News AZ's asthma drug Fasenra approved in EU A further 3,400 children are eligible for treatment with Orkambi
News Pharma collaborates to improve chances of NICE backing Duche... Project will initially focus on DMD but could benefit other rare diseases
News Spark divides opinion with $850,000 gene therapy Spark offers efficacy-based rebates and deferred payments to mitigate costs
News Shire tipped as next big pharma takeover target After trial failure, shares rallied on takeover rumours
News Ambros' $125m for pain disorder drug, and other financings Our latest crop of biofinancings has nine-figure rounds for Ambros, Atavistik, Orum, and Addition, with Link Cell and Aeovian also raising new funds.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
